Comparison A: Wt MCF7+E2 versus week 1
| |
Comparison A: Wt MCF7+E2 versus week 1
| |
Interferon signalling
|
2.79 E-07
|
Purine metabolism
|
1.13 E-12
|
Molecular mechanisms of cancer
|
1.17 E-05
|
Pyrimidine metabolism
|
2.11 E-10
|
JAK/STAT signalling
|
2.72 E-05
|
Protein ubiquitination pathway
|
6.48 E-08
|
Germ cell-steroli cell junction signalling
|
2.76 E-05
|
Role of BRCA1 in DNA damage response
|
6.92 E-08
|
Inositol phosphate metabolism
|
1.15 E-04
|
Mitotic roles of polo-like kinase
|
5.72 E-07
|
IL-3 signalling
|
1.63 E-04
|
Role of CHK proteins in cell cycle checkpoint control
|
1.41 E-06
|
PDGF signalling
|
1.94 E-04
|
ATM signalling
|
3.06 E-06
|
Neuregulin signalling
|
2.15 E-04
|
Cell cycle:G2/M DNA damage checkpoint regulation
|
1.23 E-05
|
Erythropoietin signalling
|
2.31 E-04
|
Cleavage and polyadenylation of pre-mRNA
|
1.24 E-04
|
PI3K/AKT signalling
|
2.95 E-05
|
Alanine and aspartate metabolism
|
5.15 E-04
|
Comparison B: Week 1 versus week 9
| |
Comparison B: Week 1 versus week 9
| |
Mitotic roles of polo-like kinase
|
4.71E-08
|
Antigen presentation pathway
|
8.88E-20
|
Role of CHK proteins in cell cycle checkpoint control
|
2.08E-07
|
Interferon signalling
|
1.44E-17
|
ATM signalling
|
3.27E-07
|
Activation of IRF by cytosolic pattern recognition receptors
|
2.48E-10
|
Role of BRCA1 in DNA damage and response
|
8.75E-06
|
Role of pattern recognition receptors in recognition of bacteria and viruses
|
2.37E-07
|
Hereditary breast cancer signalling
|
2.08E-05
|
Dendritic cell maturation
|
3.54E-06
|
Pyrimidine metabolism
|
3.34E-05
|
Allograft rejection signalling
|
7.64E-06
|
Cell cycle: G2/M DNA damage checkpoint regulation
|
1.57E-04
|
Autoimmune thyroid disease signalling
|
1.04E-05
|
| |
Graft-versus-host disease signalling
|
1.21E-05
|
| |
Role of RIG1-like receptors in antiviral innate immunity
|
1.39E-05
|
| |
Cross talk between dendritic cells and natural killer cells
|
2.02E-05
|
Comparison C: Wt MCF7+E2 versus week 9
| |
Comparison C: Wt MCF7+E2 versus week 9
| |
PDGF signalling
|
1.15E-07
|
Protein ubiquitination pathway
|
1.63 E-07
|
Molecular mechanisms of cancer
|
1.53E-07
|
Purine metabolism
|
6.49 E-07
|
Actin cytoskeleton signalling
|
4.92E-07
|
Pyrimidine metabolism
|
7.92 E-06
|
Integrin signalling
|
6.93E-07
|
Mitochondrial dysfunction
|
1.25 E-04
|
PI3K/AKT signalling
|
1.06E-06
|
Oxidative phosphorylation
|
2.47 E-04
|
EGF signalling
|
5.88E-06
|
Citrate cycle
|
4.79 E-04
|
FAK signalling
|
8.45E-06
|
Role of BRCA1 in DNA damage response
|
7.53 E-04
|
HGF signalling
|
1.23E-05
|
Lysine degradation
|
7.84 E-04
|
14-3-3 mediated signalling
|
1.30E-05
| | |
Neuregulin signalling
|
1.53E-05
| | |
Ephrin Receptor Signaling
|
1.66E-05
| | |
IGF-1 Signaling
|
1.85E-05
| | |
ILK Signaling
|
2.27E-05
| | |
Axonal Guidance Signaling
|
3.12E-05
| | |
JAK/Stat Signaling
|
6.14E-05
| | |
Insulin Receptor Signaling
|
6.17E-05
| | |